Company（https://www.nanoalvand.com/en/company.html）
Products（https://www.nanoalvand.com/en/products.html）
Business Development（https://www.nanoalvand.com/en/business-development.html）
Careers（https://www.nanoalvand.com/en/careers.html）
Blog（https://www.nanoalvand.com/en/blog.html）
Contact（https://www.nanoalvand.com/en/contact.html）
01 November, 2025
# Topics
nanoalvand（https://www.nanoalvand.com/en/component/tags/tag/nanoalvand.html）
hope（https://www.nanoalvand.com/en/component/tags/tag/hope.html）
OurHopeShapesTheFuture（https://www.nanoalvand.com/en/component/tags/tag/ourhopeshapesthefuture.html）
News（https://www.nanoalvand.com/en/blog-en/9-news.html）
Stomach Cancer Awareness Month
01 November, 2025
Every November reminds us of the ongoing challenge of stomach cancer, a disease that often remains unnoticed until advanced stages. Raising awareness and promoting prevention are just as important as advancing treatment options.
Several lifestyle choices can significantly reduce the risk: avoiding smoking and alcohol, maintaining a healthy weight, treating Helicobacter pylori infections, limiting processed or nitrate-rich foods, and including more fruits and vegetables in the daily diet. These simple habits play a key role in lowering the global burden of stomach cancer.
At NanoAlvand, we remain committed to this mission through continuous innovation in oncology. Our portfolio, including Fenosa®️ (Regorafenib), Tysuna®️ (Sunitinib), Xetabin®️ (Capecitabine), Alvoxal®️ (Oxaliplatin), Fiverna®️ (Fluorouracil), and Alvinotec®️ (Irinotecan Hydrochloride), supports physicians and patients in the fight against gastrointestinal and stomach malignancies. Together, these therapies represent a comprehensive approach to targeted and cytotoxic treatment, expanding access to effective, high-quality cancer care across the region.